NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, Sharon Spencer

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations

Abstract

This NCCN Task Force Report describes the management of dermatologic and ocular toxicities that occur in patients treated with epidermal growth factor receptor (EGFR) inhibitors. Task force members are from NCCN member institutions and include oncologists, dermatologists, an ophthalmologist, and a mid-level oncology provider. This report describes commonly used therapies that the task force agreed are appropriate standards of care for dermatologic and ophthalmologic toxicities associated with EGFR inhibitors, which generally are supported only by anecdotal evidence. Few recommendations are evidence based; however, some commonly used therapies have data supporting their use. Conclusions from completed clinical trials are generally limited by the small numbers of patients enrolled. The information in this report is based on available published data on treating toxicities associated with EGFR inhibitors, data from treatment of clinically similar toxicities from different etiologies, and expert opinion among the NCCN Task Force members.

Original languageEnglish (US)
Pages (from-to)5-21
Number of pages17
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue numberSUPPL. 1
DOIs
StatePublished - May 2009

Keywords

  • Acne-like rash
  • Cetuximab
  • Colorectal cancer
  • Dermatologic toxicities
  • Dry eye
  • EGFR
  • EGFR inhibitor
  • Epidermal growth factor receptor
  • Erlotinib
  • Gefitinib
  • Head and neck cancer
  • Non-small cell lung cancer
  • Ocular toxicities
  • Panitumumab
  • Papulopustular rash
  • Paronychia
  • Radiation dermatitis
  • Rash
  • TKI
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer'. Together they form a unique fingerprint.

Cite this